US4036954A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Stable prostaglandin E group-containing formulation
Assignee: Astellas Pharma Inc
•
Filing: 1974-10-21
•
Granted: 1977-07-19
•
Expires: 1994-10-21
Abstract
Abstract There is provided a process of preparing a prostaglandin E group-containing formulation by adding to a prostaglandin E group at least one additive selected from the group consisting of a thiol compound, a water soluble high molecular weight compound and a water-soluble salt of deoxycholic acid and then subjecting the mixture to lyophilization.
Inventors
- 👤 Masuo Murakami
- 👤 Shigemi Kawahara
- 👤 Hiroitsu Kawata
- 👤 Kiyoshi Okazaki
- 👤 Jun Sekino
- 👤 Hidemi Shimizu
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 10:05
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/557; C; C07; C07C; C07C405/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
50 words
A process of preparing a stable prostaglandin E group-containing formulation which comprises adding to a prostaglandin E group compound an effective amount of at least one member selected from the group consisting of hydroxypropyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, water-soluble dextrin and dextran and subjecting the resulting mixture to lyophilization.
Claim 2
Dependent Claim
50 words
A process of preparing a stable prostaglandin E group-containing formulation which comprises adding to a prostaglandin E group compound an effective amount of at least one member selected from the group consisting of hydroxypropyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, water-soluble dextrin and dextran and subjecting the resulting mixture to lyophilization.
Claim 3
Dependent Claim
27 words
A process as claimed in claim 1 wherein said prostaglandin E group compound is prostaglandin E 1 , prostaglandin E 2 , or prostaglandin E 3 .
Claim 4
Dependent Claim
43 words
A process as claimed in claim 1 wherein said prostaglandin E group compound is a member selected from the group consisting of 16-methyl-prostaglandin E 2 , 3-methyl-prostaglandin E 2 , 3,16(R)-dimethyl-prostaglandin E 2 , 17-oxo-15-epi-prostaglandin E 2 , and 16(R)-hydroxy-prostaglandin E 2 .
Claim 5
Dependent Claim
45 words
A process as claimed in claim 1 wherein when said prostaglandin E group compound is in a crystalline state, the crystal is dissolved in an organic solvent followed by removing the solvent by vaporization before the additive is added to said prostaglandin E group compound.
Claim 6
Dependent Claim
16 words
A process as claimed in claim 4 wherein said organic solvent is ethanol or ethyl acetate.
Claim 7
Dependent Claim
20 words
A process as claimed in claim 1 wherein said prostaglandin E group compound is a natural prostaglandin E group compound.
Claim 8
Dependent Claim
49 words
A process according to claim 1 in which 5 - 250 mg. of said water-soluble dextrin and dextran is added per 0.05 mg. of said prostaglandin E group compound, and 0.1 - 150 mg. of said cellulose derivative is added to 0.05 mg. of said prostaglandin E group compound.
Claim 9
Dependent Claim
44 words
A lyophilized pharmaceutical composition comprising as the active ingredient a therapeutically effective amount of a PGE group compound and an effective amount of at least one member selected from the group consisting of hydroxypropyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, dextran and water soluble dextrin.
Claim 10
Dependent Claim
44 words
A lyophilized pharmaceutical composition comprising as the active ingredient a therapeutically effective amount of a PGE group compound and an effective amount of at least one member selected from the group consisting of hydroxypropyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, dextran and water soluble dextrin.
Claim 11
Dependent Claim
21 words
A lyophilized pharmaceutical composition according to claim 8 wherein said PGE group compound is PGE 2 and the additive is dextran.
Claim 12
Dependent Claim
51 words
A lyophilized pharmaceutical composition according to claim 8 in which 5 - 250 mg. of said water-soluble dextrin and dextran is added per 0.05 mg. of said prostaglandin E group compound, and 0.1 - 150 mg. of said cellulose derivative is added to 0.05 mg. of said prostaglandin E group compound.
References Cited (Backward Citations)
US3816393A
Cited
US3826823A
Cited
US3851052A
Cited
US3917864A
Cited
US3903297A
Cited
US3954787A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-07-18 | 1981-01-17 | 1981-07-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-07-18 | 1985-01-17 | 1985-07-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-07-18 | 1989-01-17 | 1989-07-19 | $7700.00 | Window Closed / Lapsed |